bullish
Innovent Biologics Placement - Momentum Is Very Strong but past Deals Have Been Mixed
431 Views14 Jan 2021 19:04
Innovent Biologics Inc (1801 HK) is looking to raise about U$600m to fund its clinical trials and product licensing and possible M&A. This will be the fifth placement in little under two years.
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Innovent Biologics Placement - Has Ample Cash but the Discount Is Enticing11 Sep 2023
- Innovent Biologics (信达生物) Placement - Back on the Market but This Time with Secondary Selldown22 Jul 2020
- Innovent Biologics Placement: Positive Newsflow Bodes Well for Capital Raising12 Feb 2020
- Innovent Biologics - Promising Phase I Results for Lung Cancer09 Oct 2019
x